Table 1. Demographic, clinical and laboratory characteristics and outcomes of patients.
| Variable | Total |
| Demographics | |
| Number of patients (n) | 13 |
| Age (years, median (IQR)) | 39 (36–46) |
| Female sex (n, %) | 3 (23) |
| Time from onset of symptoms to presentation (days, median, (range)) | 3 (1–18) |
| Time for confirmation of diagnosis (days, median, (range)) | 4 (2–14) |
| Collection of samples (days, median (range))¥ | 2 (1–3) |
| Risk Factors for infection (n, %) | |
| Travelling to the tropics* | 10 (77) |
| Water contact* | 11 (85) |
| Direct contact to animals* | 3 (23) |
| Confirmation of diagnosis | |
| Seroconversion (n, %) | 13 (100) |
| Microscopic agglutination testing (n, %) | 1 (8) |
| Polymerase chain reaction (n, %) | 1 (8) |
| Laboratory data on admission (median (IQR)) | |
| Hemoglobin (g/dl) | 14.5 (12.1–15) |
| Platelets (106/µl) | 131 (45–156) |
| Leukocytes (103/µl) | 7.6 (5.58–8.53) |
| Creatinine (µmol/l) | 102 (86–187) |
| CRP (mg/l) | 124 (54.6–225.3) |
| Bilirubine (µmol/l) | 39.4 (17.4–54.5) |
| ALT (U/l) | 53 (28–87) |
| CK (U/l) | 147.5 (120–616.5) |
| Worst laboratory data (median (IQR)) | |
| Hemoglobin (g/dl) | 11.3 (10–12.5) |
| Platelets (106/µl) | 83 (22–131) |
| Leukocytes (103/µl) | 9.6 (6.88–12.05) |
| Creatinine (µmol/l) | 166 (86–232) |
| CRP (mg/l) | 162 (82–232.6) |
| Bilirubine (µmol/l) | 43.8 (29.1–55.3) |
| ALT (U/l) | 91 (57–162) |
| CK (U/l) | 156 (87–716) |
| Outcome | |
| Length of hospital stay (days, median, (IQR)) | 10 (9–12) |
| Need of intensive care treatment (n, %) | 6 (46) |
| Length of ICU stay (days, median, (IQR)) | 2.5 (1.3–5.3) |
| Acute Kidney Injury (n, %) | 7 (54) |
| Sepsis, total (n, %) | 8 (62) |
| Sepsis, present on admission (n, %) | 7 (54) |
| Need of mechanical ventilation (n, %) | 1 (8) |
| death (n, %) | 0 (0) |
¥
in days after admission.
*
in a direct context with the onset of the infection (<3 weeks).
Abbrevations: CRP = C-reactive protein; ALT = alanine transaminase; CK = creatine kinase; ICU = intensive care unit.